We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Alimera Negotiates with FDA to Avoid AdComm Meeting, New Clinical Trials
Alimera Negotiates with FDA to Avoid AdComm Meeting, New Clinical Trials
Discussions with Alimera ahead of a January advisory committee meeting led the FDA to conclude that the company’s diabetic macular edema drug would be approvable with labeling changes and additional safety data — foregoing the need for the meeting and additional clinical trials.